Abstract
Recently, hereditary breast and ovarian cancer syndrome (HBOC) has been increasingly recognized. The number of women with a strong family history of breast and/or ovarian cancer and young-onset triple-negative breast cancer undergoing genetic testing is increasing. At our hospital, we recommend mastectomy for breast cancer patients with BRCA1/2 germline mutations, in accordance with the NCCN guideline. In the present study, 28 patients with breast cancer were diagnosed as having BRCA 1/2 germline mutations, of which 10 had undergone genetic testing prior to surgery. Finally, all of the patients elected to undergo mastectomy. On the contrary, the remaining 18 of the 28 patients underwent genetic testing after the surgery, because they wished to be tested after the treatment of the breast cancer had been stabilized, or when they became aware of the possibility of HBOC by ipsilateral breast cancer recurrence. Of the 17 breast cancer patients who had undergone breast-conserving surgery, 7 developed ipsilateral breast cancer recurrence. We present cases of ipsilateral breast recurrence after breast-conserving surgery in women with BRCA1/2 germline mutations, and consider the optimal surgical management for breast cancer patients with HBOC.
